

The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.

The reader should not assume that the information is accurate and complete.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 13F

OMB APPROVAL	
OMB Number:	3235-0006
Estimated average burden hours per response:	23.8

FORM 13F COVER PAGE

Report for the Calendar Year or Quarter Ended: **03-31-2025**

Check here if Amendment Amendment Number:
This Amendment (Check only one.): is a restatement.
 adds new holdings entries.

Institutional Investment Manager Filing this Report:

Name: **REGENERON PHARMACEUTICALS, INC.**
Address: **777 Old Saw Mill River Road**
Tarrytown, NY 10591
Form 13F File Number: **028-24826**
CRD Number (if applicable):
SEC File Number (if applicable):

The institutional investment manager filing this report and the person by whom it is signed hereby represent that the person signing the report is authorized to submit it, that all information contained herein is true, correct and complete, and that it is understood that all required items, statements, schedules, lists, and tables, are considered integral parts of this form.

Person Signing this Report on Behalf of Reporting Manager:

Name: **Leonard Brooks**
Title: **Senior Vice President, Treasurer**
Phone: **914-847-7000**

Signature, Place, and Date of Signing:

/s/ Leonard Brooks **Sleepy Hollow, NY** **05-02-2025**
[Signature] [City, State] [Date]

Report Type (Check only one.):

- 13F HOLDINGS REPORT. (Check here if all holdings of this reporting manager are reported in this report.)
 13F NOTICE. (Check here if no holdings reported are in this report, and all holdings are reported by other reporting manager(s).)
 13F COMBINATION REPORT. (Check here if a portion of the holdings for this reporting manager are reported in this report and a portion are reported by other reporting manager(s).)

Form 13F Summary Page

Report Summary:

Number of Other Included Managers: **0**
Form 13F Information Table Entry Total: **6**
Form 13F Information Table Value Total: **1,234,240,208**
(round to nearest dollar)

List of Other Included Managers:

Provide a numbered list of the name(s) and Form 13F file number(s) of all institutional investment managers with respect to which this report is

filed, other than the manager filing this report.

[If there are no entries in this list, state "NONE" and omit the column headings and list entries.]

NONE

The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.

The reader should not assume that the information is accurate and complete.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 13F

OMB APPROVAL

OMB Number: 3235-0006
 Estimated average burden
 hours per response: 23.8

FORM 13F INFORMATION TABLE

COLUMN 1	COLUMN 2	COLUMN 3	COLUMN 4	COLUMN 5	COLUMN 6	COLUMN 7	COLUMN 8				
NAME OF ISSUER	TITLE OF CLASS	CUSIP	FIGI	VALUE (to the nearest dollar)	SHRS OR PRN AMT	SH/ PUT/ CALL	INVESTMENT DISCRETION	OTHER MANAGER	VOTING AUTHORITY		
									SOLE	SHARED	NONE
2seventy Bio, Inc.	Common Stock	901384107		6,198,845	1,254,827	SH	SOLE		1,254,827	0	0
Adicet Bio, Inc.	Common Stock	007002108		730,978	968,183	SH	SOLE		968,183	0	0
Adverum Biotechnologies, Inc.	Common Stock	00773U207		790,572	180,909	SH	SOLE		180,909	0	0
Alnylam Pharmaceuticals, Inc.	Common Stock	02043Q107	1,200,089,039	4,444,445		SH	SOLE		4,444,445	0	0
Bluebird Bio, Inc.	Common Stock	09609G209		102,480	21,000	SH	SOLE		21,000	0	0
Intellia Therapeutics, Inc.	Common Stock	45826J105		26,328,294	3,702,995	SH	SOLE		3,702,995	0	0